Navigation Links
InterMune Reports First Quarter 2011 Financial Results and Business Highlights
Date:4/28/2011

BRISBANE, Calif., April 28, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced results from operations for the first quarter ended March 31, 2011.  InterMune also highlighted its recent clinical development and business activities.  

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "First quarter events were highlighted by the announcement on March 3 that the European Commission had granted marketing authorization for Esbriet® (pirfenidone) for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis, or IPF.   The approval of Esbriet not only marks an historic moment in the treatment of IPF patients, but also an exciting new chapter for our company as we now transition to become an international commercial organization.  We are working diligently to make Esbriet available to European patients as soon as possible, beginning with Germany in September of this year."

Mr. Welch continued, "In March we met with the U.S. FDA to discuss our plan to conduct an additional Phase 3 study of pirfenidone, toward the goal of bringing pirfenidone to IPF patients in the United States.  We plan to conduct an Analyst Day in New York on May 26 to provide a comprehensive update of our commercial and scientific plans.  During this event we will provide details on ASCEND -- our new Phase 3 study -- including the study design, its scientific rationale and guidance on important study and NDA resubmission milestones.  At that time we will also share our expense guidance for 2011."  

InterMune commented, in response to speculation in recent press reports that the management and Board are very enthusiastic about the company's business plans and the company is not currently in discussions regarding a sale of the company.

Clinical Development, Business Highlights a
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Global Stem Cells Group subsidiary Adimarket ... biologic products for the regeneration and repair of human organs ... Cells Group’s ambitious expansion plans in Latin America, a commitment ... regenerative medicine and stem cell therapies. , Bioquark ... have the ability to alter the regulatory state of human ...
(Date:6/2/2015)... June 02, 2015 Research and Markets( ... PharmaBiotech,s new report "Biomarkers - Technologies, Markets ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:6/2/2015)...   Hospira, Inc. (NYSE: HSP ), ... partner, Celltrion – a global biopharmaceutical company – has received ... in Brazil – for Remsima ... in Brazil . The medication will ... biosimilar infliximab in 26 European countries and in ...
(Date:6/2/2015)... 2, 2015   Intrexon Corporation (NYSE: ... announced today the appointment of Olivier R. ... Sector.  Mr. Jarry will lead the expansion of ... applications for consumer markets.  Mr. ... experience in leading global life sciences and consumer ...
Breaking Biology Technology:Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 2Global Biomarkers Market Report 2015 - Technologies, Markets and Companies Analysis and Forecasts 2014-2024 3ANVISA Approves First Infliximab Biosimilar in Brazil 2ANVISA Approves First Infliximab Biosimilar in Brazil 3ANVISA Approves First Infliximab Biosimilar in Brazil 4ANVISA Approves First Infliximab Biosimilar in Brazil 5Intrexon Announces New Sector Leader 2Intrexon Announces New Sector Leader 3
... a development that holds much promise for the future ... of solar energy to produce clean and renewable liquid ... Lawrence Berkeley National Laboratory (Berkeley Lab) have reported a ... of the semiconductor cadmium-selenide was increased 100,000 times. ...
... , , VANCOUVER, British ... company, dedicated to the commercializing of a unique drug ... medical devices, announced today that it will present full ... catheters at the 2009 Interscience Conference on Antimicrobial Agents ...
... , GENEVA, Sept. 11 Friendly LRL ... previously-announced tender offer to acquire all of the outstanding shares ... STHK) ("Startech"), effective immediately. FLH,s offer was scheduled to ... September 30, 2009. All shares previously tendered pursuant to ...
Cached Biology Technology:Gold solution for enhancing nanocrystal electrical conductance 2Gold solution for enhancing nanocrystal electrical conductance 3Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting. 2Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting. 3Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 2Friendly LRL Holdings Terminates Offer To Acquire Startech Environmental Corporation 3
(Date:5/22/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... its promotional pricing and making the Wocket generally available for ... , Head of Marketing said, "We,ve extended the opportunity to ... of May. To get your wocket at this special price, ... store on June 1, you,ll receive a unique code that ...
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/19/2015)... , May 19, 2015 ... has announced the addition of the  "Genetic ... offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent ... an in-depth analysis of the current and ... of gene-based tests, their working principles and ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2
... -- FirstMark, the diagnostic division of GenWay ... company will be exhibiting at the inaugural Atlanta ... of Cardiology, Emory Clinical Cardiovascular Research Institute, Emory ... provide a new, needs-based and convenient forum for ...
... Center of NYU School of Medicine will hold its ... honor three outstanding leaders in biomedical research. The Dart/NYU ... in the development of pharmaceuticals and honors those scientists ... care provided at the patient,s bedside. Recipients of this ...
... VIEW, CA (April 6, 2012) Using its ... company, has found five significant genetic associations for hypothyroidism ... conducted to date. The details of the study are ... . "With nearly 90 percent of our 125,000 ...
Cached Biology News:FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update 2NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 2NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 3NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 4NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards 523andMe identifies 5 significant genetic associations for hypothyroidism 2
... The new Class II safety cabinets Heraeus HERAsafe ... and user-orientated design. ,The new frameless slanted ... work area. The new front window design makes ... The large work aperture with a height of ...
... The Jouan MSC series of ... comfortable working conditions and certification to ... automatic regulation ensures that the cabinets ... working conditions. Natural lighting, low noise ...
... a custom synthesis service for synthetic ... molecules are: Composed of 18-20 ... overhang at the 3-terminus PAGE ... and ready-to-use. Simply order your ...
... shaker stands both present the ... height, and help protect user ... tubular steel, these heavy-duty accessories ... weight and minimize the vibration ...
Biology Products: